⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27573099 | 0.97 | DGAT1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL5977714 | 0.97 | — | — | |
| SCHEMBL240584 | 0.81 | — | — | |
| Bromide SCHEMBL5516150 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL2222 | 0.79 | — | — | |
| SCHEMBL10453213 | 0.79 | — | — | |
| SCHEMBL30150871 | 0.77 | — | — | |
| SCHEMBL12482611 | 0.77 | — | — | |
| SCHEMBL8437555 | 0.77 | DGAT1 (0.42) | — | |
| SCHEMBL19865399 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251150-A | A kind of preparation method of 2,3- diaminopropionic acid methyl ester | 宁夏医科大学 | 2019-01-22 | — | — | CN | claimed |
| CN-109251150-A | A kind of preparation method of 2,3- diaminopropionic acid methyl ester | 宁夏医科大学 | 2019-01-22 | — | — | CN | disclosed |
| CN-109251150-A | A kind of preparation method of 2,3- diaminopropionic acid methyl ester | 宁夏医科大学 | 2019-01-22 | — | — | CN | disclosed |
| CN-107021895-A | Antiseptic | 尔察祯有限公司 | 2017-08-08 | — | — | CN | disclosed |
| CN-101765585-B | Antibacterial agent | 尔察祯有限公司 | 2017-03-15 | — | — | CN | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| CN-1938031-A | Biaryl substituted pyrazinones as sodium channel blockers | MERCK & CO INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1298390-C | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-02-07 | — | — | CN | disclosed |
| CN-1191063-C | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1295471-A | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-0698023-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| CN-1202893-A | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DU PONT MERCK PHARMA (US) | 1998-12-23 | — | — | CN | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| EP-0698023-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0698023-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026745-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |